CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157337" target="_blank" >RIV/00098892:_____/22:10157337 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/22:73611165

Výsledek na webu

<a href="https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1986219" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1986219</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2021.1986219" target="_blank" >10.1080/10428194.2021.1986219</a>

Jazyk výsledku

angličtina

Název v původním jazyce

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Popis výsledku v původním jazyce

CD19 is an important target for novel anti-lymphoma treatments as it is broadly and homogenously expressed across many B-cell malignancies. Approximately 30-50% of patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to first-line therapy with R-CHOP have a poor prognosis and need effective treatment options, especially those ineligible for autologous stem cell transplant (ASCT). With the emergence of cellular- and antibody-based therapies targeting CD19, it is of scientific interest to study the expression of CD19 in this patient population with few treatment options. Salles et al. recently reported durable complete responses in a significant proportion of patients with relapsed or refractory (R/R) DLBCL from the phase II study (L-MIND; NCT02399085) of tafasitamab, an Fc-modified, anti-CD19 monoclonal antibody, in combination with lenalidomide, an immunomodulatory agent. Results from L-MIND led to the US FDA approval of the tafasitamab plus lenalidomide combination as a second and subsequent line treatment option for ASCT-ineligible patients with R/R DLBCL. However, changes in CD19 expression after tafasitamab treatment may impact subsequent CD19-targeted approaches, such as CAR T-cell therapy; understanding expression changes could inform optimal sequencing of treatment options and identify treatment feasibility. Available data on this question remain limited and appear to vary by drug class and indication. An anti-CD19 (antibody-drug conjugate) immunotherapy did not preclude subsequent responses to CD19-directed CAR T-cell therapy, with maintenance of CD19 expression. This contrasts with reports of CD19 expression loss after bispecific anti-CD19 treatment and CD19-directed CAR T-cell treatments. For approved anti-CD19 therapies, more data are needed to understand treatment impact on target expression. This is the first report on CD19 expression analyzed in tumor biopsies in R/R DLBCL patients before and after tafasitamab treatment.

Název v anglickém jazyce

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Popis výsledku anglicky

CD19 is an important target for novel anti-lymphoma treatments as it is broadly and homogenously expressed across many B-cell malignancies. Approximately 30-50% of patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to first-line therapy with R-CHOP have a poor prognosis and need effective treatment options, especially those ineligible for autologous stem cell transplant (ASCT). With the emergence of cellular- and antibody-based therapies targeting CD19, it is of scientific interest to study the expression of CD19 in this patient population with few treatment options. Salles et al. recently reported durable complete responses in a significant proportion of patients with relapsed or refractory (R/R) DLBCL from the phase II study (L-MIND; NCT02399085) of tafasitamab, an Fc-modified, anti-CD19 monoclonal antibody, in combination with lenalidomide, an immunomodulatory agent. Results from L-MIND led to the US FDA approval of the tafasitamab plus lenalidomide combination as a second and subsequent line treatment option for ASCT-ineligible patients with R/R DLBCL. However, changes in CD19 expression after tafasitamab treatment may impact subsequent CD19-targeted approaches, such as CAR T-cell therapy; understanding expression changes could inform optimal sequencing of treatment options and identify treatment feasibility. Available data on this question remain limited and appear to vary by drug class and indication. An anti-CD19 (antibody-drug conjugate) immunotherapy did not preclude subsequent responses to CD19-directed CAR T-cell therapy, with maintenance of CD19 expression. This contrasts with reports of CD19 expression loss after bispecific anti-CD19 treatment and CD19-directed CAR T-cell treatments. For approved anti-CD19 therapies, more data are needed to understand treatment impact on target expression. This is the first report on CD19 expression analyzed in tumor biopsies in R/R DLBCL patients before and after tafasitamab treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

1029-2403

Svazek periodika

63

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

468-472

Kód UT WoS článku

000718734500001

EID výsledku v databázi Scopus

2-s2.0-85119436073